|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Seoul National University Hospital Korea Health Industry Development Institute |
|---|---|
| Information provided by: | Seoul National University Hospital |
| ClinicalTrials.gov Identifier: | NCT00862108 |
Purpose
The purpose of this study is to determine whether norepinephrine gene polymorphism affect to treatment response in ADHD
| Condition | Intervention | Phase |
|---|---|---|
|
Attention Deficit Hyperactivity Disorder |
Drug: Methylphenidate |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Open Label, Single Group Assignment, Efficacy Study |
| Official Title: | Functional Brain Markers and Predictors of Treatment Response Associated With Norepinephrine System Genes in ADHD |
| Estimated Enrollment: | 50 |
| Study Start Date: | September 2008 |
| Estimated Study Completion Date: | March 2010 |
| Estimated Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Methylphenidate: Experimental |
Drug: Methylphenidate
mg/kg dose: 0.7~1.2mg/kg PO daily morning intake 8 weeks
|
Eligibility| Ages Eligible for Study: | 6 Years to 18 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Soo-Churl Cho, MD, PhD | 82-2-2072-3648 | jewook.kang@gmail.com |
| Korea, Republic of | |
| Seoul National University Hospital | Recruiting |
| Seoul, Korea, Republic of, 110-769 | |
| Principal Investigator: Soo-Churl Cho, MD, PhD | |
| Principal Investigator: | Soo-Churl Cho, MD, PhD | Seoul National University College of Medicine |
More Information
| Responsible Party: | Seoul National University Hospital ( Je-Wook, Kang ) |
| Study ID Numbers: | A080054 |
| Study First Received: | March 5, 2009 |
| Last Updated: | March 13, 2009 |
| ClinicalTrials.gov Identifier: | NCT00862108 History of Changes |
| Health Authority: | South Korea: Institutional Review Board |
|
Attention Deficit Hyperactivity Disorder Polymorphism, Single Nucleotide SLC6A2 protein, human ADRA2A protein, human Polymorphism, Single Nucleotide |
|
Dopamine Uptake Inhibitors Neurotransmitter Agents Attention Deficit and Disruptive Behavior Disorders Methylphenidate Central Nervous System Stimulants Dyskinesias Signs and Symptoms Dopamine |
Attention Deficit Disorder with Hyperactivity Mental Disorders Mental Disorders Diagnosed in Childhood Norepinephrine Hyperkinesis Neurologic Manifestations Dopamine Agents |
|
Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Disease Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Nervous System Diseases Attention Deficit and Disruptive Behavior Disorders Methylphenidate Central Nervous System Stimulants Dyskinesias |
Pharmacologic Actions Signs and Symptoms Pathologic Processes Attention Deficit Disorder with Hyperactivity Mental Disorders Therapeutic Uses Mental Disorders Diagnosed in Childhood Hyperkinesis Neurologic Manifestations Dopamine Agents Central Nervous System Agents |
